Archive for July, 2019
Zhejiang takes the lead in implementing DRGs payment
On July 18th, the Zhejiang Medical Insurance Bureau issued the “Opinions on Promoting the Reform of Basic Medical Insurance Payment Methods for Medical Communities in Zhejiang Province,” and plans to implement multiple and composite medical insurance payment methods under total budget management. For inpatient medical services, the payment is mainly based on the DRGs (Diagnosis-Related Groups) system. For long-term and chronic disease inpatient medical services, the “daily payment for each sickbed” will be gradually promoted. For outpatient medical services, the “per-head payment” will be implemented, which also combines the “Contracted Family Doctor Services”.
市场洗牌来了！浙江率先全面推行DRGs点数法付费
来源：医药网 2019.07.19
7月18日，浙江省医保局发布《关于推进全省县域医共体基本医疗保险支付方式改革的意见》，计划全面推行总额预算管理下的多元复合式医保支付方式；对住院医疗服务，主要按DRGs（疾病诊断相关分组）点数法付费；对长期、慢性病住院医疗服务，逐步推行按床日付费；对门诊医疗服务探索结合家庭医生签约服务，实行按人头付费。
“Guideline” for “Internet+Health Care” in Shandong province released
On July 11th, the Shandong Provincial Government issued the “Notification on the Construction Plan for Promoting a Demonstration Province of ‘Internet+Health Care’ from 2019 to 2020.” The “Notification” stipulates that to achieve the real-time exchange and sharing of medical data, the construction of a “traceability system of drugs,” a “pre-warning and detecting system of medicines in short supply,” and a “prescription circulation platform” should be promoted. The “Notification” indicates that the construction of “Internet Hospitals” based on medical institutes is encouraged, and the “consulting or prescribing medicine over the internet” should be widely implemented in Shandong province from 2020.
山东“互联网+医疗健康”的路线图， 来了！
来源：医药网 2019.07.15
核心提示：7月11日，山东省人民政府发布《关于印发山东省推进“互联网+医疗健康”示范省建设行动计划（2019-2020年）的通知》（以下简称《通知》）。《通知》指出，应加快药品追溯体系、短缺药品检测预警系统以及处方流转平台的建设，实现医疗数据的实时交换和共享。《通知》明确，鼓励建设依托医疗机构发展的互联网医院，2020年起应普遍开展互联网诊疗服务。
“List of National Intensive Monitoring Drug” is released
On July 1st, the Medical Administration Bureau of the National Health Commission issued the “Notification on printing the first List of National Intensive Monitoring Drug (Chemicals and Biological Products),” 20 drugs were selected in the “List.” The “Notification” stipulates that all provinces should form a list of provincial intensive monitoring drug on the basis of the national “List” and publish it for use by various medical institutions. All medical institutions should establish a regulatory system for monitoring drugs and strengthen the management of clinical applications of them. At the same time, the prescription management of drugs outside the “List” should also be strengthened.
重磅！国家重点监控药品目录公布
来源：医药网 2019.07.02
核心提示：7月1日，国家卫健委医政医管局发布了《关于印发第一批国家重点监控合理用药药品目录（化药及生物制品）的通知》，共20个药品入选。 《通知》要求， 各省应在《目录》基础上形成省级重点监控合理用药药品目录并公布，以供各类医疗机构参考；各医疗机构要建立重点监控合理用药药品管理制度，加强目录内药品临床应用的全程管理；同时，还应加强目录外药品的处方管理。
“Drug Evaluation Report in 2018” is released
On July 1st, the National Medical Products Administration(NMPA) issued the “Drug Evaluation Report in 2018.” The “Report” shows that the Drug Evaluation Centre of the NMPA reviewed and approved 106 new drugs in 2018. Although the number of applications for registration of new drugs has increased by 47%, the evaluation time has been reduced significantly in comparison to 2017. Benefiting from the accelerated drug evaluation reforms, the number of applications for registration of innovative drugs has increased significantly in 2018, of which 85% were from domestic companies. At the same time, in order to improve the quality of generic drugs, the Drug Evaluation Centre has made every effort to promote the “Quality Consistency Evaluation for Generic Drugs,” and there were eight batches of generic drugs that are involved in comparison to 2018.
《2018年度药品评审报告》发布
来源：中国医药报 2019.07.01
核心提示：7月1日，国家药品监管局发布《2018年度药品评审报告》（以下简称《报告》）。《报告》显示，2018年国家药监局药品评审中心共审评通过106个新药；新药注册申请较2017年增长了47%，但注册申请审评用时明显下降；受益于药审改革加速，2018年创新药注册申请数量大幅增长，其中85%的注册申请来自国内企业；同时，为提升我国仿制药质量，药品审评中心全力推进仿制药治疗和疗效一致性评价工作，2018年全年正式发布了8批参比制剂目录。